Hepatic Disease in Patients With HIV

  • Author: Mark S. Sulkowski, MD (More Info)
  • Editors in Chief: Joseph J. Eron, Jr., MD; Daniel R. Kuritzkes, MD
  • Last Reviewed: 11/13/21 (What's New)

Summary

  • AASLD/IDSA guidance panel recommends highly active DAA regimens as preferred therapy for HCV treatment of persons with HIV and genotype 2-6 HCV coinfection (Table 10) (Management Guidelines)[AASLD-IDSA HCV]
  • EASL guidance panel recommends highly active DAA regimens for HCV treatment of persons with HIV and genotype 2-6 HCV coinfection (Table 11) (Management Guidelines)[EASL HCV]

Action required